Dissociated incretin response to oral glucose at 1 year after restrictive vs. malabsorptive bariatric surgery

Aim: Compare the response to oral glucose of the two incretin hormones, glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) at 1 year after restrictive vs. malabsorptive bariatric surgery.

[1]  S. Woods,et al.  The effects of GLP-1 infusion in the hepatic portal region on food intake , 2009, Regulatory Peptides.

[2]  J. Teixeira,et al.  Do Incretins Play a Role in the Remission of Type 2 Diabetes after Gastric Bypass Surgery: What are the Evidence? , 2009, Obesity surgery.

[3]  M. Rickels,et al.  Narrative Review: Effect of Bariatric Surgery on Type 2 Diabetes Mellitus , 2009, Annals of Internal Medicine.

[4]  E. Jonas,et al.  High revision rates after laparoscopic vertical banded gastroplasty. , 2009, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[5]  G. Mingrone.  Role of the incretin system in the remission of type 2 diabetes following bariatric surgery. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[6]  J. Teixeira,et al.  Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. , 2008, The Journal of clinical endocrinology and metabolism.

[7]  M. Blaser,et al.  The Effect of Laparoscopic Gastric Banding Surgery on Plasma Levels of Appetite-Control, Insulinotropic, and Digestive Hormones , 2008, Obesity surgery.

[8]  Margaret Anderson,et al.  Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. , 2008, JAMA.

[9]  A. Halpern,et al.  Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35 , 2008, Surgical Endoscopy.

[10]  J. Holst,et al.  GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. , 2007, American journal of physiology. Endocrinology and metabolism.

[11]  J. Holst,et al.  Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. , 2007, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[12]  S. Woods,et al.  Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. , 2007, Endocrinology.

[13]  J. Kral,et al.  Surgical treatment of obesity , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[14]  S. Ikramuddin,et al.  Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: a preliminary study. , 2007, The Journal of surgical research.

[15]  N. Irwin,et al.  Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets , 2007, Diabetologia.

[16]  N. Irwin,et al.  Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice , 2007, Diabetologia.

[17]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[18]  W. Schwesinger,et al.  Metabolic aspects of bariatric surgery. , 2007, The Medical clinics of North America.

[19]  L. Sjöström.  Surgical intervention as a strategy for treatment of obesity , 2000, Endocrine.

[20]  J. Marescaux,et al.  The Mechanism of Diabetes Control After Gastrointestinal Bypass Surgery Reveals a Role of the Proximal Small Intestine in the Pathophysiology of Type 2 Diabetes , 2006, Annals of surgery.

[21]  F. Rubino.  Bariatric surgery: effects on glucose homeostasis , 2006, Current opinion in clinical nutrition and metabolic care.

[22]  G. Ballantyne.  Peptide YY(1-36) and Peptide YY(3-36): Part II. Changes after Gastrointestinal Surgery and Bariatric Surgery: Part I. Distribution, Release and Actions appeared in the last issue (May 2006) , 2006, Obesity surgery.

[23]  A. Brazzale,et al.  Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance test , 2005, Diabetologia.

[24]  S. Woods,et al.  Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. , 2005, American journal of physiology. Endocrinology and metabolism.

[25]  J. Holst,et al.  On the Physiology of GIP and GLP-1 , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[26]  Henry Buchwald,et al.  Bariatric surgery: a systematic review and meta-analysis. , 2004, JAMA.

[27]  H. Jacobsson,et al.  Distal Small Bowel Hormones (Correlation with Fasting Antroduodenal Motility and Gastric Emptying) , 1998, Digestive Diseases and Sciences.

[28]  B. Ahrén,et al.  Improved beta-cell function after standardized weight reduction in severely obese subjects. , 2003, American journal of physiology. Endocrinology and metabolism.

[29]  F. Folli,et al.  Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. , 2002, The Journal of clinical endocrinology and metabolism.

[30]  Yuichiro Yamada,et al.  Inhibition of gastric inhibitory polypeptide signaling prevents obesity , 2002, Nature Medicine.

[31]  S. Toubro,et al.  The role of postprandial releases of insulin and incretin hormones in meal-induced satiety—effect of obesity and weight reduction , 2001, International Journal of Obesity.

[32]  Andrea Mari,et al.  A Model-Based Method for Assessing Insulin Sensitivity From the Oral Glucose Tolerance Test , 2001 .

[33]  J. Holst,et al.  Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.

[34]  H Wedel,et al.  Differentiated long-term effects of intentional weight loss on diabetes and hypertension. , 2000, Hypertension.

[35]  P. Hellström,et al.  Importance of Small Bowel Peptides for the Improved Glucose Metabolism 20 Years after Jejunoileal Bypass for Obesity , 1998, Obesity surgery.

[36]  S. Rössner,et al.  Reduced food intake after jejunoileal bypass: a possible association with prolonged gastric emptying and altered gut hormone patterns. , 1997, The American journal of clinical nutrition.

[37]  E. Näslund,et al.  Seven year results of vertical banded gastroplasty for morbid obesity. , 1997, The European journal of surgery = Acta chirurgica.

[38]  G. Mingrone,et al.  Reversibility of insulin resistance in obese diabetic patients: role of plasma lipids , 1997, Diabetologia.

[39]  J. Holst,et al.  Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans , 1994, Diabetes.

[40]  T. M. Hayes,et al.  Obesity is associated with increased post-prandial GIP levels which are not reduced by dietary restriction and weight loss. , 1989, Diabete & metabolisme.

[41]  J. Holst,et al.  Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. , 1983, The Journal of clinical endocrinology and metabolism.

[42]  E. Mason.  Vertical banded gastroplasty for obesity. , 1982, Archives of surgery.

[43]  A. Andersen,et al.  Plasma enteroglucagon after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio. , 1979, Scandinavian journal of gastroenterology.

[44]  L. Backman.  The rate of weight loss after intestinal bypass operations for obesity. An analysis of factors of significance. , 1975, Acta chirurgica Scandinavica.

[45]  L. Backman,et al.  Small-intestinal length. An intraoperative study in obesity. , 1974, Acta chirurgica Scandinavica.